The prevention of viral recurrence in the long term

Digestive and Liver Disease

Volumn 41, Issue SUPPL. 2, 2009, Pages

  Marzano, A ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Hepatitis B; Immunoglobulins; Liver; Transplantation

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; INFECTION CONTROL; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REINFECTION; RISK REDUCTION; TREATMENT INDICATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TREATMENT OUTCOME;

EID: 66149139469     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(09)60444-8     Document Type: Article

References (19)

1. Hwang S., Lee S.G., Ahn C.S., Kim K.H., Moon D.B., Ha T.Y., et al. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 14 (2008) 770-778
2. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
3. Lok A.S. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 8 (2002) S67-S73
4. Fagiuali S., Mirante V.G., Pompili M., Gianni S., Leandro G., Rapaccini G.L., et al. Liver transplantation: the Italian experience. Dig Liver Dis 34 (2002) 640-648
5. Marzano A., Gaia S., Ghisetti V., Carenzi S., Premoli A., Debernardi-Venon W., et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 11 (2005) 402-409
6. Todo S., Demetris A.J., Van Thiel D., Teperman L., Fung J.J., Starzl T.E., et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13 (1991) 619-626
7. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
8. Marzano A., Gaia S., Ghisetti V., Carenzi S., Premoli A., Debernardi-Venon W., et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 11 (2005) 532-538
9. Samuel D., Forns X., Berenguer M., Trautwein C., Burroughs A., Rizzetto M., et al. Report of the Monothematic EASL Conference on liver transplantation in viral hepatitis. J Hepatol 45 (2006) 127-143
10. Mutimer D., Dusheiko G., Barrett C., Grellier L., Ahmed M., An-schuetz G., et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 70 (2000) 809-815
11. Buti M., Mas A., Prieto M., Casafont F., González A., Miras M., et al. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 84 (2007) 650-654
12. Zheng S., Chen Y., Liang T., Lu A., Wang W., Shen Y., and Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobu-lin prophylaxis. Liver Transpl 12 (2006) 253-258
13. Wong S.N., Chu C.J., Wai C.T., Howell T., Moore C., Fontana R.J., et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13 (2007) 374-381
14. Rosenau J., Kreutz T., Kujawa M., Bahr M.J., Rifai K., Hooman N., et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46 (2007) 635-644
15. Dickson R.C., Terrault N.A., Ishitani M., Reddy K.R., Sheiner P., Luketic V., et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 12 (2006) 124-133
16. Gane E.J., Angus P.W., Strasser S., Crawford D.H., Ring J., Jeffrey G.P., et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterol-ogy 132 (2007) 931-937
17. Hooman N., Rifai K., Hadem J., Vaske B., Philipp G., Priess A., et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 14 (2008) 435-442
18. Marzano A., Androne P., Volpes R., Canova D., Cursaro C., Riili A., et al. Pharmacokinetics, efficacy and safety of intramuscular and intravenous of hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation. Dig Liver Dis 40 (2008) A16
19. Filipponi F., Carrai P., De Simone P., Franchello A., Romagnoli R., and Sal-izzoni M. Efficacy, safety and pharmacokinetic profile of pasteurized intramuscular anti-hepatitis B immunoglobulin for the prophylaxis of hepatitis B virus recurrence after liver transplantation. Dig Liver Dis 39 (2007) A34